Mazdutide — World‘s First GCG/GLP-1 Dual-Receptor Agonist for Weight Management Approved for Market!
Time:2025-07-16
Views:28
On June 27, Innovent Biologics, Inc. ‘ Mazdutide Injection received approval from China‘s National Medical Products Administration (NMPA) for long-term weight control in adults with obesity or overweight. This marks the world’s first glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual-receptor agonist for weight loss. Its mechanism of action activates both the GLP-1 receptor (reducing appetite and calorie intake) and the GCG receptor (increasing energy expenditure and promoting fat burning), thereby significantly enhancing weight loss efficacy.
Overweight and obesity not only impact personal appearance but also substantially elevate the risk of cardiovascular, endocrine, certain cancers, respiratory, reproductive, and skeletal diseases, severely impairing patients’ quality of life. With rising rates of adult overweight and obesity, the market for weight management medications continues to expand.
In recent years, GLP-1 receptor agonists have driven explosive growth in the weight-loss drug market, including Novo Nordisk’s semaglutide (marketed in glucose-control and weight-loss formulations), liraglutide, and Eli Lilly’s tirzepatide. Multiple Chinese pharmaceutical companies are now developing biosimilar versions of these drugs while exploring new targets and mechanisms of action to collectively advance the therapeutic landscape for weight management.
.jpg)
Wechat
Jolin
Yuzhu Lin
Ciel Wong
whatsapp